India Launches First Indigenous Vaccine Against Infectious Bovine Rhinotracheitis (IBR)

Indian Immunologicals Limited (IIL) has introduced Raksha-IBR, India’s first glycoprotein E (gE) deleted DIVA marker vaccine targeting Infectious Bovine Rhinotracheitis (IBR).

Key Highlights:

• Purpose: The vaccine addresses infertility, abortions, and reduced milk productivity caused by IBR.

• Disease Background:

  • IBR is endemic in India, caused by Bovine Herpes Virus (BHV-1).

  • Transmission occurs via aerosols and infected semen from bulls.

  • Leads to reproductive issues and lower milk output.

• Innovation:

  • Marker vaccine (DIVA): Helps differentiate between infected and vaccinated animals.

  • Developed by IIL in collaboration with NDDB after years of research.

• Launch Event: Held during NDDB’s diamond jubilee in Anand, Gujarat, attended by:

  • Narendra Pal Gangwar, Secretary, Department of Animal Husbandry & Dairying

  • Meenesh C. Shah, NDDB Chairman

  • K. Anand Kumar, MD of IIL

Significance:

• Ensures sustainable productivity in India, the world’s largest milk producer.

• Protects genetically superior bulls, ensuring their semen contributes effectively to herd improvement.

• Marks a milestone in India’s veterinary vaccine development, offering systematic prevention for a disease without prior treatment or vaccine in the country.